HIV Long Terminal Repeat

"HIV Long Terminal Repeat" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Regulatory sequences important for viral replication that are located on each end of the HIV genome. The LTR includes the HIV ENHANCER, promoter, and other sequences. Specific regions in the LTR include the negative regulatory element (NRE), NF-kappa B binding sites , Sp1 binding sites, TATA BOX, and trans-acting responsive element (TAR). The binding of both cellular and viral proteins to these regions regulates HIV transcription.

Descriptor ID	D016325
MeSH Number(s)	G02.111.570.080.708.850.400 G05.360.080.708.850.400
Concept/Terms	HIV Long Terminal Repeat HIV Long Terminal Repeat LTR, Human Immunodeficiency Virus Human Immunodeficiency Virus LTR Long Terminal Repeat, HIV Human Immunodeficiency Virus Long Terminal Repeat Trans-Acting Responsive Region, HIV Trans-Acting Responsive Region, HIV Trans Acting Responsive Region, HIV HIV Trans-Acting Responsive Region HIV Trans Acting Responsive Region Trans-Activation Responsive Element, HIV Trans Activation Responsive Element, HIV Trans-Activation Responsive Region, HIV Trans Activation Responsive Region, HIV TAR Element, HIV HIV TAR Element HIV TAR Elements TAR Elements, HIV Sp1-Binding Site, HIV Sp1-Binding Site, HIV Sp1 Binding Site, HIV HIV Sp1-Binding Site HIV Sp1 Binding Site HIV Sp1-Binding Sites Sp1-Binding Sites, HIV HIV-1 LTR HIV-1 LTR HIV 1 LTR LTR, HIV-1 Negative Regulatory Element, HIV Negative Regulatory Element, HIV HIV Negative Regulatory Element

Below are MeSH descriptors whose meaning is more general than "HIV Long Terminal Repeat".

Biological Sciences [G]
Chemical Phenomena [G02]
Biochemical Phenomena [G02.111]
Molecular Structure [G02.111.570]
Base Sequence [G02.111.570.080]
Repetitive Sequences, Nucleic Acid [G02.111.570.080.708]
Terminal Repeat Sequences [G02.111.570.080.708.850]
HIV Long Terminal Repeat [G02.111.570.080.708.850.400]
Genetic Phenomena [G05]
Genetic Structures [G05.360]
Base Sequence [G05.360.080]
Repetitive Sequences, Nucleic Acid [G05.360.080.708]
Terminal Repeat Sequences [G05.360.080.708.850]
HIV Long Terminal Repeat [G05.360.080.708.850.400]

Below are MeSH descriptors whose meaning is related to "HIV Long Terminal Repeat".

Below are MeSH descriptors whose meaning is more specific than "HIV Long Terminal Repeat".

HIV Long Terminal Repeat
HIV Enhancer

publications

Timeline | Most Recent

This graph shows the total number of publications written about "HIV Long Terminal Repeat" by people in this website by year, and whether "HIV Long Terminal Repeat" was a major or minor topic of these publications.

Bar chart showing 16 publications over 11 distinct years, with a maximum of 3 publications in 2002 and 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2002	1	2	3
2003	0	1	1
2004	0	1	1
2005	0	1	1
2006	1	0	1
2007	0	1	1
2010	0	1	1
2011	3	0	3
2012	0	1	1
2015	0	2	2

Below are the most recent publications written about "HIV Long Terminal Repeat" by people in Profiles.

Tyagi M, Weber J, Bukrinsky M, Simon GL. The effects of cocaine on HIV transcription. J Neurovirol. 2016 06; 22(3):261-74.

View in: PubMed
Sahu G, Farley K, El-Hage N, Aiamkitsumrit B, Fassnacht R, Kashanchi F, Ochem A, Simon GL, Karn J, Hauser KF, Tyagi M. Cocaine promotes both initiation and elongation phase of HIV-1 transcription by activating NF-?B and MSK1 and inducing selective epigenetic modifications at HIV-1 LTR. Virology. 2015 Sep; 483:185-202.

View in: PubMed
Blazkova J, Murray D, Justement JS, Funk EK, Nelson AK, Moir S, Chun TW, Fauci AS. Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol. 2012 May; 86(9):5390-2.

View in: PubMed
Van Duyne R, Guendel I, Narayanan A, Gregg E, Shafagati N, Tyagi M, Easley R, Klase Z, Nekhai S, Kehn-Hall K, Kashanchi F. Varying modulation of HIV-1 LTR activity by Baf complexes. J Mol Biol. 2011 Aug 19; 411(3):581-96.

View in: PubMed
Lalonde MS, Lobritz MA, Ratcliff A, Chamanian M, Athanassiou Z, Tyagi M, Wong J, Robinson JA, Karn J, Varani G, Arts EJ. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog. 2011 May; 7(5):e1002038.

View in: PubMed
Tyagi S, Ochem A, Tyagi M. DNA-dependent protein kinase interacts functionally with the RNA polymerase II complex recruited at the human immunodeficiency virus (HIV) long terminal repeat and plays an important role in HIV gene expression. J Gen Virol. 2011 Jul; 92(Pt 7):1710-1720.

View in: PubMed
Sundaravaradan V, Mehta R, Harris DT, Zack JA, Ahmad N. Differential expression and interaction of host factors augment HIV-1 gene expression in neonatal mononuclear cells. Virology. 2010 Apr 25; 400(1):32-43.

View in: PubMed
Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 2007 Dec 12; 26(24):4985-95.

View in: PubMed
Kim YK, Bourgeois CF, Pearson R, Tyagi M, West MJ, Wong J, Wu SY, Chiang CM, Karn J. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J. 2006 Aug 09; 25(15):3596-604.

View in: PubMed
Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, Fisher J, Sierra M, Thomson MM, Najera R, Frank I, Kulkosky J, Pomerantz RJ, Nunnari G. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest. 2005 Jan; 115(1):128-37.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement